How long will branded GLP-1s be protected from generics?
Generic semaglutide won't reach the US until at least 2032; tirzepatide's patents don't begin expiring until 2036 — contrast India, where Novo's semaglutide patent expired in March 2026 and Dr Reddy's won approval to sell generic semaglutide there.
A long time, by US standards. According to Stanford Medicine, generic semaglutide will not be available in the US until at least 2032, when Novo's first main patent expires, and Lilly's tirzepatide patents do not begin to expire until 2036. This contrasts with other markets: Novo's semaglutide patent in India expired in March 2026, and Indian manufacturer Dr Reddy's won approval to sell generic semaglutide there. Sandoz has also challenged a key semaglutide patent in Europe. The long US exclusivity window means that, absent negotiation or voluntary price cuts, American patients and payers will continue to pay branded prices for most of the next decade. This is why the pricing deals and Medicare negotiation matter so much.